Taken together, these findings indicate the potential for the broad use of CAIX/CAXII inhibitors in combination with standard of care chemotherapy to enhance therapeutic response, reduce toxicity, and combat therapeutic resistance across multiple cancer types [9]. The gene discussed is CA12; the disease is cancer.